As of mid-August 2026, no peer-reviewed Phase 3 (randomized, adequately powered) efficacy result for psilocybin in bipolar II or anorexia is published.

By mid-August 2026, there will likely be no large, rigorous clinical trial results published showing whether psilocybin actually works for bipolar II disorder or anorexia nervosa. The studies done so far have been small and exploratory — more like checking whether it's safe and feasible to run a trial, not proving the drug works. Big, definitive trials in these conditions haven't even gotten close to finishing.

Existing bipolar II and anorexia psilocybin data are single-arm/open-label feasibility studies that cannot establish efficacy. No registered Phase 3 trials in these indications are near readout, so near-term the evidence base stays preliminary.